Biochemical properties of renin and prorenin binding to the (pro)renin receptor

Hypertension Research

Volumn 33, Issue 2, 2010, Pages 91-97

  Nabi, A H M Nurun ^a   Suzuki, Fumiaki ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

'handle' region peptide; 'hinge' region peptide; (P)RR blocker; (pro)renin receptor; Decoy peptide

Indexed keywords

ALISKIREN; ANGIOTENSIN; HANDLE REGION PEPTIDE; HINGE REGION PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PRORENIN; PRORENIN RECEPTOR; RENIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; BINDING AFFINITY; BINDING SITE; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; DIABETIC NEPHROPATHY; DISSOCIATION CONSTANT; GLOMERULOSCLEROSIS; HEART MUSCLE FIBROSIS; HUMAN; MICHAELIS CONSTANT; NONHUMAN; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; PROTEINURIA; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; BINDING SITES; HUMANS; RECEPTORS, CELL SURFACE; RENIN; STRUCTURE-ACTIVITY RELATIONSHIP; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 76349117647     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.201     Document Type: Review

References (70)

1. Re RN. Cellular biology of the renin-angiotensin systems. Arch Intern Med 1984; 144: 2037-2041.
2. Frohlich ED, Iwata T, Sasaki O. Clinical and physiologic significance of local tissue renin-angiotensin systems. Am J Med 1989; 87: 19s-22s.
3. Lever AF. Renin: endocrine, paracrine, or part-paracrine control of blood pressure? Am J Hypertens 1989; 2: 276-285.
4. Campbell DJ. Extrarenal renin and blood pressure regulation: an alternative viewpoint. Am J Hypertens 1989; 2: 266-275.
5. Baxter JD, Perloff D, Hsueh W, Biglieri EG. The endocrinology of hypertension. In: Felig P, Baxter JD, Frohman LA (eds). Endocrinology and Metabolism, 3rd edn McGraw, McHill: New York, 1995 pp 749-853.
6. Lutterotti NV, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues: a review of experimental evidence. Circulation 1994; 89: 458-470.
7. Krop M, Danser AH. Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. Curr Hypertens Rep 2008, 112-118.
8. Hsueh WA, Do YS, Wang PH. Observations on the renal processing and sorting of prorenin. Can J Physiol Pharmacol 1991; 69: 1327-1330.
9. Leckie BJ, Birnie G, Carachi R. Renin in Wilms' tumor: prorenin as an indicator. J Clin Endocrinol Metab 1994; 79: 1742-1746.
10. Luetsher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417.
11. Inagami T. Purification of renin and prorenin. Hypertension 1991; 18: 241-251.
12. Morris BJ. Molecular biology of renin I: gene and protein structure, synthesis and processing. J Hypertens 1992; 10: 209-214.
13. Suzuki F, Tanaka N, Takeuchi K, Muramoto Y, Inagami T, Murakami K, Nakamura Y. Acid-activation of rat prorenin following non-proteolytic alteration. In: Takahashi K (ed). Aspartic Proteinases. Plenum Publishing Co.: New York, 1995 pp 267-272.
14. Baxter JD, James MN, Chu WN, Duncan K, Haidar MA, Carilli CT, Reudelhuber TL. The molecular biology of human renin and its gene. Yale J Biol Med 1989; 62: 493-501.
15. Heinrikson RL, Hui J, Zurcher-Neely H, Poorman RA. A structural model to explain the partial catalytic activity of human prorenin. Am J Hypertens 1989; 2: 367-380.
16. Carilli CT, Vigne JL, Wallace LC, Smith LM, Wong MA, Lewicki JA, Baxter JD. Characterization of recombinant human prorenin and renin. Hypertension 1988; 11: 713-716.
17. Wang PH, Do YS, Macaulay L, Shinagawa T, Anderson PW, Baxter JD, Hsueh WA. Identification of renal cathepsin B as a human prorenin-processing enzyme. J Biol Chem 1991; 266: 12633-12638.
18. Morris BJ. Activation of human inactive ('Pro') renin by cathepsin D and pepsin. J Clin Endocrinol Metab 1978; 46: 153-157.
19. Dzau VJ, Gonzalez D, Kaempfer C, Dubin D, Wintroub B. Human neutrophils release serine proteases capable of activating prorenin. Circ Res 1987; 60: 595-601.
20. Derkx FHM, Tan-Tjiong L, Veld AJM, Schalekamp MPA, Schalekamp MADH. Activation of inactive plasma renin by tissue kallikreins. J Clin Endocrinol Metab 1979; 49: 765-769.
21. Chantal M, Isabelle J, Robert D, Nabil GS, Timothy LR. Prohormone convertase PC5 is a candidate processing enzyme for prorenin in the human adrenal cortex. Hypertension 1996; 28: 840-846.
22. Morris BJ. Molecular biology of renin I: gene and protein structure, synthesis and processing. J Hypertens 1992; 10: 209-214.
23. Pitarresi TM, Rubattu S, Heinrikson R, Sealey JE. Reversible cryoactivation of recombinant human prorenin. J Biol Chem 1992; 267: 11753-11759.
24. Suzuki F, Hayakawa M, Nakagawa T, Uddin MN, Ebihara A, Iwasawa A, Ishida Y, Nakamura Y, Kazuo M. Human prorenin has 'gate and handle' regions for its non-proteolytic activation. J Biol Chem 2003; 278: 22217-22222.
25. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T Sraer JD. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
26. Nabi AHMN, Kageshima A, Uddin MN, Nakagawa T, Park EY, Suzuki F. Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med 2006; 18: 483-488.
27. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJ, Burcklé CA, Müller DN, Bader M, Nguyen G, Danser AH. Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor. J Hypertens 2007; 25: 2441-2453.
28. Zhang J, Noble NA, Border WA, Owens RT, Huang Y. Receptor-dependent prorenin activation and induction of PAI-1 expression in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 2008; 295: E810-E819.
29. Nurun NA, Uddin MN, Nakagawa T, Iwata H, Ichihara A, Inagami T, Suzuki F. Role of 'handle' region of prorenin prosegment in the non-proteolytic activation of prorenin by binding to membrane anchored (pro)renin receptor. Front Biosci 2007; 12: 4810-4817.
30. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AHMN, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the 'handle' region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135.
31. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AN, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin II-indepen-dent glomerulosclerosis in human renin/prorenin receptor transgenic rats. J Am Soc Nephrol 2007; 18: 1789-1795.
32. Burckle CA, Jan Danser AH, Muller DN, Garrelds IM, Gasc JM, Popova E, Plehm R, Peters J, Bader M, Nguyen G. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006; 47: 1-5.
33. Ichihara A, Sakoda M, Kurauchi-Mito A, Kaneshiro Y, Itoh H. Involvement of (pro)renin receptor in the glomerular filtration barrier. J Mol Med 2008; 86: 629-635.
34. Ichihara A, Sakoda M, Mito-Kurauchi A, Itoh H. Activated prorenin as a therapeutic target for diabetic nephropathy. Diab Res Clin Prac 2008; 82: S63-S66.
35. Ichihara A, Sakoda M, Kurauchi-Mito A, Kaneshiro Y, Itoh H. Renin, prorenin and the kidney: a new chapter in an old saga. J Nephrol 2009; 22: 306-311.
36. Danser AHJ, van Kats JP, Admiraal PJJ, Derkx FHM, Lamers JMJ, Verdouw PD, Saxena PR, Schalekamp MADH. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24: 37-48.
37. Katz SA, Opsahl JA, Lunzer MM, Forbis LM, Hirsch AT. Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Hypertension 1997; 30: 259-266.
38. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Danser AHJ, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-688.
39. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113.
40. Saris JJ, t Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH. Prorenin induces intracellular signalling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48: 564-571.
41. Sakoda M, Ichihara A, Kaneshiro Y, Takemitsu T, Nakazato Y, Nabi AH, Nakagawa T, Suzuki F, Inagami T, Itoh H. (Pro)renin receptor-mediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007; 30: 1139-1146.
42. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke-Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1155-1166.
43. Suzuki F. Non-proteolytic activation of prorenin by the (pro)renin receptor is blocked by decoy peptide. J Renin Angiotensin Aldosterone Syst 2007; 8: 101-103.
44. Nabi AHMN, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. Decoy peptide region (RIFLKRMPSI) of prorenin prosegment plays a crucial role in prorenin binding to the (pro)renin receptor. Int J Mol Med 2009; 24: 83-89.
45. Nabi AHMN, Biswas KB, Nakagawa T, Ichihara A, Inagami T, Suzuki F. Prorenin has high affinity multiple binding sites for (pro)renin receptor. Biochim Biophys Acta 2009; 1794: 1838-1847.
46. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, Nishiyama A, Itoh H. Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J Am Soc Nephrol 2007; 18: 2054-2061.
47. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Nakagawa T, Nishiyama A, Kawachi H, Shimizu F, Inagami T. Contribution of non-proteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 2006; 17: 2495-2503.
48. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900.
49. Shan Z, Cuadra AE, Sumners C, Raizada MK. Characterization of a functional (pro)renin receptor in rat brain neurons. Exp Physiol 2008; 93: 701-708.
50. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M. Cardiovascular effects of prorenin blockade in genetically hypertensive rats (SHR) on normal and high salt diet. Am J Physiol Heart circ Physiol 2008; 295: H1117-H1121.
51. He M, Zhang L, Shao Y, Wang X, Huang Y, Yao T, Lu L. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur J Pharmacol 2009; 606: 155-161.
52. Yokota H, Takamiya A, Nagaoka T, Kitaya N, Mori F, Hikichi T, Yoshida A, Ishida Y, Suzuki F. A peptide corresponding to handle region for nonproteolytic activation of prorenin inhibits retinal neovascularization in a retinopathy of prematurity model. Invest Ophthalmol Vis Sci 2005; 46 E-Abstract 4108.
53. Satofuka S, Ichihara A, Nagai N, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Itoh H, Oike Y, Ishida S. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 2007; 48: 422-429.
54. Satofuka S, Ichihara A, Nagai N, Yamashiro K, Koto T, Shinoda H, Noda K, Ozawa Y, Inoue M, Tsubota K, Suzuki F, Oike Y, Ishida S. Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest Ophthalmol Vis Sci 2006; 47: 2686-2692.
55. Muller DN, Klanke B, Feldt S, Cordasic N, Hartner A, Schmieder RE, Luft FC, Hilgers KF. (Pro)renin receptor peptide inhibitor 'handle-region' peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008; 51: 676-681.
56. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 2009; 53: 1062-1069.
57. Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
58. Jensen C, Herold P, Brunner HR. Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008; 7: 399-410.
59. Trimarchi H, Orias M. Aliskiren and the kidney: beyond hypertension. Nephrol Rev 2009; 1: 1-4.
60. Krop M, Garrelds IM, de Bruin RJA, van Gool JMG, Fisher NDL, Hollenberg NK, Danser AHJ. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension 2008; 52: 1076-1083.
61. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136.
62. Szelke M, Leckie B, Hallett A, Jones DM, Sueiras J, Atrash B, Lever AF. Potent new inhibitors of human renin. Nature 1982; 299: 555-557.
63. Dunn BM, Deyrup C, Moesching WG, Gilbert WA, Nolan RJ, Trach ML. Inhibition of pepsin by zymogen activation fragments. Spectrum of peptides released from pepsino-gen NH2 terminus and solid phase synthesis of two inhibitory peptide sequences. J Biol Chem 1978; 253: 7269-7275.
64. Harboe M, Andersen PM, Foltman B, Kay J, Kassell B. The activation of bovine pepsinogen. Sequence of the peptides released, identification of a pepsin inhibitor. J Biol Chem 1974; 249: 4487-4494.
65. Cumin F, Evin G, Fehrentz JA, Seyer R, Castro B, Menard I, Corvol P. Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem 1985; 260: 9154-9157.
66. Paige LA, Christensen DJ, Grøn H, Norris JD, Gottlin EB, Padilla KM, Chang C, Ballas LM, Hamilton PT, Mcdonnell DP, Fowlkes D. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER a and ER b. Proc Natl Acad Sci USA 1999; 96: 3999-4004.
67. De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem 1980; 255: 7108-7117.
68. 1 receptor activation is dependent upon two juxtaposed asparagine residues on transmembrane helices III and VII. J Cell Biol 1997; 272: 4245-4251.
69. Wei Y, Czekay RP, Robillard L, Kugler MC, Zhang F, Kim KK, Xiong J, Humphries MJ, Chapman HA. Regulation of a5b1 integrin conformation and function by urokinase receptor binding. J Cell Biol 2005; 168: 501-511.
70. Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 2009; 53: 1077-1082.